Roche will present over 40 abstracts on blood disorders at the 66th American Society of Hematology Annual Meeting. Key presentations include five-year data from the POLARIX study, showing durable responses and a positive trend in overall survival for patients with first-line diffuse large B-cell lymphoma. Other presentations will cover the efficacy and safety of Lunsumio, Columvi, Venclexta/Venclyxto, and PiaSky.